Answers are grounded in this paper and cite their sources.
Proteome-wide screening uncovers dozens of novel latent cereblon interactors, highlighting privileged starting points for molecular glue degrader design.
Molecular glue degraders (MGDs), such as pomalidomide, induce degradation of non-native substrates by the cullin-RING E3 ligase 4 (CRL4) through its substrate receptor cereblon (CRBN). Here, to explore CRBN programmability, we tested whether reported CRBN–MGD substrates are part of a network of latent CRBN interactors, proteins capable of MGD-induced CRBN binding without detectable degradation. Leveraging a highly parallel protein complementation assay (GluePCA) to measure MGD-induced interaction between CRBN and zinc fingers, we identified ~210 zinc fingers bound to CRBN–pomalidomide, where top binders are already reported as degraded by dedicated MGDs. To map latent CRBN–MGD interactions proteome-wide and define the accessible CRBN interaction space, we combined artificial intelligence-derived protein surface queries (MaSIF-mimicry) with GluePCA. This pipeline identified 6 known and 43 novel CRBN–pomalidomide binders, including orthogonally validated hits. We find that these binders provide privileged starting points for MGD development. We expect this binding-focused workflow to be applicable to other MGD–E3 ligase systems, potentially extending the scope of this emerging drug class.
No takes yet. Share an insight, caveat, or question.
Galli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: